On June 4, 2020, Cardiol Therapeutics Inc. (TSX: CRDL) announced the closing of its previously announced bought deal short form prospectus offering of units for aggregate gross proceeds of $17,250,000 which includes the full exercise of the over-allotment option.
The offering was completed by a syndicate of underwriters led by Canaccord Genuity Corp. and included Raymond James Ltd., AltaCorp Capital Inc., and Echelon Wealth Partners Inc.
Cardiol is a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases.
Gowling WLG advised Cardiol with respect to this offering with a team that included Brett Kagetsu, Tara Amiri-Khaledi, Jill Dunn, Raymond Ong, Jason Mullins and Sarah Baddeley (corporate finance) and Brent Kerr and Anita Yuk (tax), with the assistance of paralegal Toni Vodola.
Read the original article on GowlingWLG.com
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.